{"title":"公司推出了锕-225合资企业","authors":"None Rick Mullin","doi":"10.1021/cen-10136-buscon14","DOIUrl":null,"url":null,"abstract":"Isotope Technologies Munich (ITM), a German radiopharmaceutical firm, and Canadian Nuclear Laboratories (CNL) are forming a joint venture for the industrial-scale production of actinium-225 ( 225 Ac). The rare, α-emitting medical radioisotope is of interest as a precision oncology therapy. The venture, Actineer, plans to build a dedicated actinium production facility in an unspecified location. It will begin supplying 225 Ac in the interim; CNL will provide starting material for irradiation at its laboratory in Chalk River, Ontario, and ITM will process the resulting 225 Ac to pharmaceutical-grade material. CNL operates a national laboratory at Chalk River on behalf of Atomic Energy of Canada.","PeriodicalId":9517,"journal":{"name":"C&EN Global Enterprise","volume":"30 ","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Firms launch an actinium-225 venture\",\"authors\":\"None Rick Mullin\",\"doi\":\"10.1021/cen-10136-buscon14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Isotope Technologies Munich (ITM), a German radiopharmaceutical firm, and Canadian Nuclear Laboratories (CNL) are forming a joint venture for the industrial-scale production of actinium-225 ( 225 Ac). The rare, α-emitting medical radioisotope is of interest as a precision oncology therapy. The venture, Actineer, plans to build a dedicated actinium production facility in an unspecified location. It will begin supplying 225 Ac in the interim; CNL will provide starting material for irradiation at its laboratory in Chalk River, Ontario, and ITM will process the resulting 225 Ac to pharmaceutical-grade material. CNL operates a national laboratory at Chalk River on behalf of Atomic Energy of Canada.\",\"PeriodicalId\":9517,\"journal\":{\"name\":\"C&EN Global Enterprise\",\"volume\":\"30 \",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"C&EN Global Enterprise\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/cen-10136-buscon14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"C&EN Global Enterprise","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/cen-10136-buscon14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Isotope Technologies Munich (ITM), a German radiopharmaceutical firm, and Canadian Nuclear Laboratories (CNL) are forming a joint venture for the industrial-scale production of actinium-225 ( 225 Ac). The rare, α-emitting medical radioisotope is of interest as a precision oncology therapy. The venture, Actineer, plans to build a dedicated actinium production facility in an unspecified location. It will begin supplying 225 Ac in the interim; CNL will provide starting material for irradiation at its laboratory in Chalk River, Ontario, and ITM will process the resulting 225 Ac to pharmaceutical-grade material. CNL operates a national laboratory at Chalk River on behalf of Atomic Energy of Canada.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
